Partnering, licensing, and collaboration are essential to our business and the end-goal of all our commercialization efforts. We depend on these activities to create lasting and growing value from our proven innovation. To this end Micropharma has focused significant resources to build a team, process, and company to make these relationships successful.
Micropharma is always interested in building new relationships, growing existing ones, and working with interested, qualified investors who would like be part of our growing company.
April 25, 2013
Micropharma Limited, today announced that after three years of development it has a timeline for launch of its ingestible gastrointestinal sampling technology. The company released its plans to launch the device in late 2014 commercially for research and development use and later for specific clinical applications. Micropharma has been developing the device for three years and in the last year has expedited the project by partnering with StarFish Medical a medical device development company that offers a full complement of design and manufacturing solutions. The partnership will see StarFish Medical improve and finalize the design of the autonomous multiple sample acquisition and localization technologies, design for manufacture, produce initial devices, as well as to engineer for cost effectiveness.
April 02, 2013
Micropharma Limited today announced that the International Preliminary Report on Patentability gave their epsilon-poly-lysine microcapsule PCT patent claims broad approval. Dr. Jones commented that "it is clear from the report on patentability that all broad claims on formulation are novel, inventive and industrially applicable" and continued "almost all of the claims were found patentable which was not surprising given the unexpected improvements over previous technologies and the novelty of the formulation". The patent claims a capsule comprising a core and a capsular wall comprising epsilon(e)-poly-lysine or a derivative thereof.